Please login to the form below

Not currently logged in
Email:
Password:

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

RxC International EMD Serono James HoyesJames Hoyes has joined RxC International as an executive partner, having worked for the New Jersey management consulting firm as a senior advisor since 2014.

He was previously president of EMD Serono - as the US biopharma operations of Germany's Merck are known - having initially joined the company in 2004 as VP of neurology marketing.

Hoyes subsequently held roles as executive vice president, managing EMD Serono's neurology sales, marketing, comms, call centre and medical affairs operations, and as chief commercial officer.

Prior to joining EMD Serono, Hoyes held leadership positions with the likes of Serono, Elan and Sanofi.

In his new consultancy role he will provide advisory services to RxC's clients, work on corporate development initiatives in life sciences and implement key strategic initiatives to scale up the firm's global operations.

RxC International managing partner Subbarao Jayanthi said: “Jim's addition represents another milestone in the expansion of our business. He has an outstanding track record as a leader in the life sciences sector, and his deep strategic and executive leadership expertise will be invaluable to our clients.”

12th August 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics